Inventiva Pharma is a biopharmaceutical company focused on developing treatments for fibrotic and orphan diseases, including NASH, systemic scleroderma and mucopolysaccharidosis. The company is listed on Euronext Paris (IVA) and is advancing a pipeline built on a technology platform informed by fibrosis mechanisms. Inventiva maintains a chemical library of over 240,000 molecules and uses cell models, including patient cells, to accelerate discovery of therapeutic candidates. Its lead compound, lanifibranor, is being progressed through preparatory studies toward a Phase III trial for NASH and systemic sclerosis. A second program, odiparcil, is being developed as a candidate for multiple forms of mucopolysaccharidosis. The company raised €35.5M to fund these clinical and development activities.

Total raised

$44M

Funding rounds

1

Latest round

Equity

Latest activity

Apr 2018